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ABSTRACT
We have previously reported that the removal of a 20-nucleotide sequence, termed the D sequence, from both ends of the inverted ter-
minal repeats (ITRs) in the adeno-associated virus serotype 2 (AAV2) genome significantly impairs rescue, replication, and encapsida-
tion of the viral genomes (X. S. Wang, S. Ponnazhagan, and A. Srivastava, J Mol Biol 250:573–580, 1995; X. S. Wang, S. Ponnazhagan,
and A. Srivastava, J Virol 70:1668 –1677, 1996). Here we describe that replacement of only one D sequence in either ITR restores each of
these functions, but DNA strands of only single polarity are encapsidated in mature progeny virions. Since most commonly used re-
combinant AAV vectors contain a single-stranded DNA (ssDNA), which is transcriptionally inactive, efficient transgene expression
from AAV vectors is dependent upon viral second-strand DNA synthesis. We have also identified a transcription suppressor sequence
in one of the D sequences, which shares homology with the binding site for the cellular NF-B-repressing factor (NRF). The removal of
this D sequence from, and replacement with a sequence containing putative binding sites for transcription factors in, single-stranded
AAV (ssAAV) vectors significantly augments transgene expression both in human cell lines in vitro and in murine hepatocytes in vivo.
The development of these genome-modified ssAAV vectors has implications not only for the basic biology of AAV but also for the opti-
mal use of these vectors in human gene therapy.
IMPORTANCE
The results of the studies described here not only have provided novel insights into some of the critical steps in the life cycle of a
human virus, the adeno-associated virus (AAV), that causes no known disease but have also led to the development of novel re-
combinant AAV vectors which are more efficient in allowing increased levels of gene expression. Thus, these studies have signifi-
cant implications for the potential use of these novel AAV vectors in human gene therapy.
The wild-type (WT) adeno-associated virus (AAV) is a non-pathogenic member of the Parvoviridae family with a 4.7-kb
single-stranded DNA (ssDNA) genome (1). It has gained particu-
lar attention because recombinant AAV (rAAV) vectors represent
one of the most promising viral vector systems for gene therapy
(2) and are currently in use in a number of gene therapy clinical
trials (3). Most rAAV vectors used in clinical trials are single-
stranded vectors. We and others have demonstrated that viral sec-
ond-strand DNA synthesis is one of the major rate-limiting steps
in single-stranded AAV (ssAAV) vector-mediated transgene ex-
pression (4–7). Recently, the development of self-complementary
AAV (scAAV) vectors, which can bypass the requirement of viral
second-strand DNA synthesis (8–10), has shown remarkable effi-
cacy in the treatment of hemophilia B patients (11). However, a
major limitation of scAAV vectors is their packaging capacity,
which is 2.5 kb. Such a limited packaging capacity excludes
many larger therapeutic genes. When common promoters such as
the cytomegalovirus (CMV) promoter and chicken -actin (CBA)
promoter are used, a cDNA of less than 1.2 kb can be packaged
into the scAAV vectors. The inclusion of many tissue-specific pro-
moters, such as the human alpha-1 antitrypsin (hAAT) promoter,
further excludes many therapeutic genes, for instance, the human
factor VIII gene (12). Therefore, strategies to improve the trans-
duction efficiency of conventional ssAAV vectors are needed.
Both WT and rAAV genomes contain inverted terminal re-
peats (ITRs) of 145 nucleotides (nt) at both ends. The terminal
125 nucleotides in each ITR form a palindromic double-stranded
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T-shaped hairpin structure (1), in which the A-A= palindrome
forms the stem and the two smaller palindromes, B-B= and C-C=,
form the cross-arms of the T. The other 20 nucleotides (D se-
quence) in the ITR remain single stranded. The ssD[] sequence
is always at the 3= end, whereas the complementary one, the
ssD[] sequence is invariably at the 5= end. Once in the cells, the
single-stranded genome undergoes second-strand DNA synthesis,
which turns both the ssD[] and ssD[] sequences into double-
stranded D[] (dsD[]) sequences. Our laboratory has previ-
ously documented that phosphorylated forms of a 52-kDa cellular
chaperone protein, FKBP52 (FK506-binding protein), specifically
interact with the ssD[] sequence and hence inhibit viral second-
strand DNA synthesis and subsequent transgene expression (7,
13–15). On the other hand, dephosphorylation of FKBP52 at ty-
rosine residues by the cellular T-cell protein tyrosine phosphatase
(TC-PTP) and at serine/threonine residues by protein phospha-
tase 5 (PP5) prevents FKBP52 from binding to the ssD[] se-
quence, leading to efficient viral second-strand DNA synthesis
(14, 16).
What role the ssD[] sequence plays during the life cycle of
AAV still remains unclear, although we have previously demon-
strated the existence of a cellular protein which specifically inter-
acts with the ssD[]-sequence probe (6). Following purification
and mass spectrometry, the cellular protein binding with the
ssD[] sequence was found to have partial amino acid homology
to NF-B-repressing factor (NRF), a negative regulator of tran-
scription (NRF) (17). Since both the cellular proteins binding
with either the ssD[] or ssD[] sequence have the potential to
inhibit transgene expression mediated by ssAAV vectors and since
we have previously reported that the removal of the D sequences
from the viral genome impairs rescue, replication, and encapsida-
tion of AAV DNA (18–20), we wished to examine whether resto-
ration of one D sequence in the ssAAV genome might not only
restore rescue, replication, and encapsidation but also enhance
transgene expression from ssAAV vectors. We report here that the
ssD[]-sequence-substituted ssAAV genomes could be success-
fully packaged into rAAV vectors and that the transduction effi-
ciency of these vectors was significantly higher than that of con-
ventional ssAAV vectors.
MATERIALS AND METHODS
Cell lines, DNA primers, and 32P-labeled probes. Human cervical cancer
(HeLa), embryonic kidney (HEK293), and osteosarcoma (U2OS) cells
were purchased from American Type Culture Collection (Manassas, VA,
USA). Human hepatocellular carcinoma (Huh7) cells were described pre-
viously (21). All cells were maintained in complete Dulbecco modified
Eagle medium (C-DMEM) (Mediatech Inc., Manassas, VA, USA) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma-
Aldrich, St. Louis, MO, USA) and 1% penicillin and streptomycin (P/S)
(Lonza, Walkersville, MD). Cells were grown as adherent cultures in a
humidified atmosphere at 37°C in 5% CO2, subcultured after treatment
with trypsin-Versene mixture (Lonza, Walkersville, MD) for 2 to 5 min at
room temperature (RT), washed, and resuspended in complete medium.
Primer pairs specific for CMVenhancer-F (5=-TCCCATAGTAACGC
CAATAGG-3=) and CMVenhancer-R (5=-CTTGGCATATGATACACTT
GATG-3=) were used in encapsidation assays. EcoRI- and XhoI-doubly
digested or XhoI- and RsrII-doubly digested plasmids pAAV-hrGFP, fol-
lowed by gel recovery, were used as DNA templates to generate 32P-labled
humanized recombinant green fluorescent protein (hrGFP) and
hGH(A)n probes, respectively. Briefly, DNA templates were denatured by
heating for 10 min at 100°C, followed by rapid chilling in an ice bath.
Random-primed labeling was performed using Klenow enzyme (Roche,
Indianapolis, IN, USA) following the manufacturer’s instructions. 32P-
labeled probes were then purified with a MicrospinTM G-50 column (GE
Healthcare, Piscataway, NJ, USA). To determine the polarity of the AAV
vector genomes, two sets of identical slot blot membranes were hybridized
separately with each one of the following two complementary oligonucle-
otides derived from hrGFP: probe hrGFP(), 5=-GGGGAAGCTCTGGA
TGAAGAAGTCGCT-3=, and probe hrGFP(), 5=-AGCGACTTCTTCA
TCCAGAGCTTCCCC-3=. The oligonucleotides were labeled prior to the
hybridization using the digoxigenin (DIG) oligonucleotide 3=-end-label-
ing kit (Roche, Indianapolis, IN, USA) as per the manufacturer’s instruc-
tions.
AAV DNA rescue and replication assays. Equivalent amounts of each
of the recombinant AAV plasmids were transfected in HEK293 cells to-
gether with pACG2 and pHelper by the triple-plasmid transfection pro-
tocol. At 72 h posttransfection, low-Mr DNA samples were isolated by the
procedure described by Hirt (22) and digested extensively with DpnI at
100 U/ml for 2 h in a buffer containing 50 mM potassium acetate, 20 mM
Tris-acetate, 10 mM magnesium acetate, and 1 mM dithiothreitol (DTT).
DpnI-treated samples were analyzed on Southern blots using 32P-labeled
DNA probes specific for the hrGFP.
AAV DNA encapsidation assays. Equivalent amounts of each of the
recombinant AAV plasmids were transfected together with pACG2 and
pHelper by the triple-plasmid transfection protocol in HEK293 cells in
6-well plates. Cells were harvested at 72 h posttransfection, subjected to 3
rounds of freeze-thawing, and then digested with 50 U/ml Benzonase
(EMD Millipore, Darmstadt, Germany) at 37°C for 1 h. Cell lysates were
then centrifuged at 4,000 rpm for 30 min. Equivalent amounts of super-
natants were deproteinized to release the rAAV genomes by incubation at
65°C for 30 min in NaOH at a final concentration of 100 mM. The viral
DNA was purified with the DNA Clean & Concentrator-5 kit (Zymo Re-
search, Irvine, CA, USA) and subjected to quantitative PCR (qPCR) as-
says.
Recombinant AAV vectors. Highly purified stocks of AAV2 vectors,
containing a CMV promoter driving the hrGFP expression gene or con-
taining a CBA promoter driving the firefly luciferase expression gene,
were packaged by the triple-plasmid transfection protocol (23, 24).
Briefly, HEK293 cells were cotransfected with three plasmids using poly-
ethylenimine (PEI) (linear; molecular weight [MW], 25,000) (Poly-
sciences, Inc., Warrington, PA), and medium was replaced at 6 h post-
transfection. Cells were harvested at 72 h posttransfection, subjected to 3
rounds of freeze-thawing, and then digested with 100 U/ml Benzonase
(EMD Millipore, Darmstadt, Germany) at 37°C for 1 h. Viral vectors were
purified by iodixanol (Sigma, St. Louis, MO) gradient ultracentrifugation
followed by ion-exchange chromatography using HiTrap Q HP (GE
Healthcare, Piscataway, NJ), washed with phosphate-buffered saline
(PBS), and concentrated by centrifugation using centrifugal spin concen-
trators with a 150,000-molecular-weight cutoff (MWCO). Viral vectors
were resuspended in 500 l PBS.
Quantitative DNA slot blot analyses. The physical genomic titers of
recombinant vector stocks were determined by quantitative DNA slot blot
analysis as previously described (25). Briefly, 10 l vector stocks was di-
gested with 100 U/ml Benzonase (EMD Millipore, Darmstadt, Germany)
at 37°C for 1 h. An equal volume of 200 mM NaOH was added, followed
by incubation at 65°C for 30 min. A known quantity of plasmid DNA was
also treated in the same manner for use as a standard reference during
quantitation. DNA samples were loaded in 2-fold serial dilutions onto
Immobilon-NY membranes (Millipore, Bedford, MA). After cross-
linking, the membranes were then prehybridized for 6 h at 68°C in 25 ml
hybridization solution containing 6	 SSC (1	 SSC is 0.15 M NaCl plus
0.015 M sodium citrate), 100 g/ml freshly boiled herring sperm DNA,
0.5% sodium dodecyl sulfate (SDS), and 5	 Denhardt’s reagent. Subse-
quently, the membranes were hybridized with freshly boiled 32P-labeled
DNA probe in a total volume of 25 ml of hybridization solution at 68°C for
18 to 20 h. Membranes were then washed once in 50 ml wash solution 1
(2	 SSC, 0.1% SDS) at RT for 15 min and twice in 50 ml wash solution 2
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(0.1	 SSC, 0.1% SDS) at 68°C for 30 min and then exposed to Biomax
MRTM X-ray films (Kodak, Rochester, NY) at 70°C.
Southern blot analyses. The viral DNA samples isolated from AAV
DNA rescue and replication assays were purified with the DNA Clean &
Concentrator-5 kit (Zymo Research, Irvine, CA, USA), dissolved in 20 l
double-distilled water (ddH2O), and electrophoresed on 1.2% neutral
agarose gels. DNA was transferred to nylon membranes. Briefly, the gel
was equilibrated at RT with solution I (0.25 M HCl) for 20 min, solution
II (1 M NaCl, 0.5 M NaOH) for 40 min, and solution III (1 M NaCl, 0.5 M
Tris-HCl) for 40 min. The DNA was transferred to Immobilon-NY
membranes (Millipore, Bedford, MA) in 20	 SSC. After UV cross-link-
ing, the membranes were treated as described above.
Western blot assays. Western blot assays were performed as previ-
ously described (26). Briefly, viral stocks were boiled for 10 min with
loading buffer, electrophoresed using 12% SDS-PAGE, electrotransferred
to nitrocellulose membranes (Bio-Rad), and probed with antibody B1
(ARP, Waltham, MA, USA) at 4°C overnight. The membranes were then
incubated with horseradish peroxidase-conjugated secondary antibodies
(1:5,000 dilution; GE Healthcare, Piscataway, NJ, USA) and detected with
an enhanced chemiluminescence substrate (MEMD Millipore, Billerica,
MA, USA).
Recombinant AAV vector transduction in vitro. Cells were seeded in
96-well plates at 10,000 cells per well in C-DMEM. AAV infections were
performed in serum- and antibiotic-free DMEM for 2 h, followed by
extensive washes with PBS to remove the vector inoculum. Transgene
expression was analyzed by fluorescence microscopy at 72 h posttransduc-
tion. Alternatively, transgene expression was also analyzed by flow cytom-
etry at 72 h posttransduction.
Animal handling. All animal experiments were performed according
to the guidelines for animal care specified by the Animal Care Services at
the University of Florida (Gainesville, FL). Six- to 10-week-old C57BL/6J
male mice were purchased from Jackson Laboratory (Bar Harbor, ME)
and maintained at the University of Florida College of Medicine (Gaines-
ville, FL). The Institutional Animal Care and Use Committee approved all
protocols for the care and use of these mice.
Recombinant AAV vector transduction in vivo. Recombinant
ssAAV2 vectors were injected intravenously via the tail vein into C57BL/6J
mice at 1 	 1010 vector genomes (vgs) per animal. Phosphate-buffered
saline (PBS)-injected mice were used as an appropriate control. For the
fluorescence reporter gene, mice livers were harvested at 2, 4, and 6 weeks
after vector administration, and thin sections from each hepatic lobe were
mounted on slides and visualized under a fluorescence microscope. For
the luciferase reporter gene, in vivo Fluc imaging was done as described
previously (27). Briefly, mice were weighed to calculate the volume of
substrate according to the dose of 4 mg/kg of body weight and anesthe-
tized. The calculated volume of the 5-mg/ml stock substrate solution was
mixed with 100 l of PBS and injected via the intraperitoneal route. In
vivo bioluminescence imaging was acquired immediately over a period of
5 min using a Xenogen machine equipped with a cooled charge-coupled
device camera (Xenogen, Alameda CA). Signal intensity was quantified
using the camera control program, Living Image software, and shown as
photons/second/cm2/steridian (p/s/cm2/sr).
Statistical analysis. Results are presented as mean  standard devia-
tion (SD). Differences between groups were identified using a grouped




One D sequence restores rescue, replication, and encapsidation
of recombinant AAV genomes. To examine the consequences of
replacement of the D sequence in either ITR, the following two
plasmids containing the identical expression cassette of a CMV
promoter-driven humanized recombinant green fluorescent pro-
tein (hrGFP), flanked by two wild-type (WT) AAV2 ITRs of 145
nucleotides (Fig. 1A, top), were constructed: (i) pLC1-hrGFP, in
which the D sequence in the left ITR was replaced with a non-AAV
substitute (S) sequence (Fig. 1A, middle), and (ii) pLC2-hrGFP, in
which the D sequence in the right ITR was replaced with the S
sequence (Fig. 1A, bottom). The S sequence was chosen due to the
fact that this specific oligonucleotide does not interact with the
cellular proteins that bind with the D sequences (6), and that the S
sequence does not compete with the D sequence (20). In addition,
in each of the rAAV genomes, the terminal resolution sites (trs) in
both ITRs remain functional (18–20), and the entire vector ge-
nome size is larger than 2.8 kb, which exceeds the packaging ca-
pacity of self-complementary AAV (scAAV) vectors (9, 10), to
ensure that only virions containing ssAAV genomes were pack-
aged (28–30).
Recombinant AAV genome rescue and replication assays were
performed following cotransfection of these plasmids separately
into HEK293 cells with AAV (pACG2) and adenovirus helper
(pHelper) plasmids. Low-Mr DNA samples were isolated at vari-
ous time points posttransfection, extensively digested with DpnI,
and analyzed on Southern blots using a 32P-labeled hrGFP-spe-
cific DNA probe. These results are shown in Fig. 1B. The kinetics
of rAAV genome rescue and replication from both mutant plas-
mids pLC1-hrGFP and pLC2-hrGFP were nearly the same as that
from pAAV-hrGFP, as determined by time-dependent accumula-
tion of monomeric (m) and dimeric (d) forms of rAAV DNA
replicative intermediates, albeit less efficiently. These results
nonetheless suggest that the presence of one D sequence in either
of the two ITRs is necessary and sufficient for the rescue and rep-
lication of the rAAV genomes. These results further corroborate
that the trs in each of the D-sequence-substituted genomes was
functional, since both m and d forms of rAAV DNA replicative
intermediates were detected, in contrast to the accumulation of
only duplex DNA that occurs when scAAV vectors are used, which
have a mutation in one trs (10).
The S sequence is retained during AAV DNA rescue and rep-
lication. Since previous studies have shown that one ITR can serve
as a template to repair the other ITR during AAV DNA rescue and
replication (31), it was important to determine whether the D
sequence in one ITR displaced the S sequence in the other ITR. To
this end, low-Mr DNA samples isolated at 72 h posttransfection
were digested with DpnI, followed by digestion with or without
BglII restriction endonuclease. The schematic structures of vari-
ous DNA replicative intermediates are depicted in Fig. 1D. The S
sequence contains an additional BglII site, and following digestion
with BglII, the WT and the D-sequence-substituted AAV genomes
would be expected to produce unique sets of restriction fragments
that are consistent with the presence of both tail-to-tail (T-T) and
head-to-head (H-H) configurations, provided that the S sequence
is not repaired. Southern blot analysis of BglII-digested DNA frag-
ments using a 32P-labeled probe specific for hrGFP produced the
expected bands of 2.11 kb and 4.22 kb for pAAV-hrGFP (Fig. 1C,
lane 6). Similarly, a band of 1.968 kb for pLC1 (Fig. 1C, lane 4) and
two bands of 2.155 kb and 4.31 kb for pLC2 (Fig. 1C, lane 5) were
also detected. In addition, the presence of the expected DNA
bands (Fig. 1D) in each corresponding group demonstrated that
the S sequence was retained during viral DNA replication. These
results demonstrate that the S sequence in viral replicative DNA
intermediates derived from pLC1 and pLC2 is not repaired during
rescue and replication.
One D sequence restores encapsidation of the mutant AAV
genomes. To examine whether the viral genomes rescued and
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replicated from mutant plasmids could also undergo encapsida-
tion into viral capsids, a standard triple-plasmid transfection pro-
tocol was used to generate rAAV vectors as described in Materials
and Methods. Following digestion with Benzonase to degrade any
unencapsidated DNA, equivalent volumes of virus stocks were
deproteinized to release the rAAV genome and 2-fold serial dilu-
tions were analyzed on quantitative DNA slot blots using a 32P-
labeled hrGFP DNA probe. These results, shown in Fig. 2A, dem-
onstrate that the presence of one D sequence in one of the two
ITRs is necessary and sufficient for packaging of the AAV genome,
although the vector titers appeared to be 50% of those of the
unmodified vectors, presumably because progeny strands of only
[] or [] polarity were being encapsidated. Similar results were
obtained with multiple rounds (n  3 for each vector) of packag-
ing of two different transgenes (data not shown). Analysis of the
purified DNA on alkaline agarose gels revealed the same 2.8-kb
genome from all three rAAV-hrGFP vectors and no detectable
linear monomers of 5.6 kb, indicating that scAAV vectors were not
generated (Fig. 2B). Analysis of the denatured capsid proteins
from purified viral stocks on SDS-polyacrylamide gels, followed
by Western blotting, also revealed a classic VP1/VP2/VP3 protein
ratio of 1:1:10 (Fig. 2C). Interestingly, however, further analyses
revealed that in contrast to plasmid pAAV-hrGFP, from which
ssAAV vectors of both polarities were generated as expected, the
use of both mutant plasmids pLC1-hrGFP and pLC2-hrGFP led to
the generation of predominantly only single-polarity vectors, as
determined by using hrGFP-specific oligonucleotide probes of ei-
ther [] or [] polarity (Fig. 2D). For the most part, the
hrGFP() probe hybridized to the minus strand, whereas the
hrGFP() probe hybridized to the plus strand of the viral DNA.
Thus, replacement of one D sequence from one ITR leads to the
generation of AAV vectors containing a single-polarity genome.
These data suggest that AAV genomes containing the D[] se-
quence substitution generated from both pLC1-hrGFP and pLC2-
hrGFP plasmids undergo successful encapsidation, an observa-
tion also consistent with previously published reports (32, 33).
One D sequence is sufficient for replication of recombinant
AAV genomes. To test whether the replacement of one D se-
quence affects viral DNA replication, HEK293 cells were infected
with vAAV-hrGFP, vLC1-hrGFP, or vLC2-hrGFP vectors indi-
vidually, followed by transfection with pHelper and pACG2 plas-
mids. Plasmid pAAV-hrGFP was included as an appropriate con-
trol. The viral replication intermediates were isolated at 72 h
postinfection, digested with DpnI or/and BglII, and analyzed on
Southern blots using 32P-labeled DNA probes specific for hrGFP
or poly(A) sequences, respectively. These results, shown in Fig. 3,
indicated that both mutant viral genomes replicated at a level sim-
ilar to that for the parental vAAV-hrGFP viral genomes.
FIG 1 Effect of one D-sequence substitution on viral genome rescue and replication. (A) Schematic structures of recombinant AAV genomes. HP, hairpin
structure; D, D sequence; S, substitute sequence; CMVp, cytomegalovirus promoter; hrGFP, humanized recombinant green fluorescent protein; hGH(A)n,
human growth hormone poly(A) signal. (B) Southern blot analysis for rescue and replication of AAV genomes from recombinant plasmids. (C) Southern blot
analysis for the structural integrity of the replicative DNA intermediates containing substitutions in the D sequence. Following digestion with or without BglII,
the DNA fragments were analyzed by neutral agarose gel electrophoresis. (D) Schematic representation of structures of the replicative DNA intermediates of
recombinant AAV genomes containing substitutions in the D sequence. The monomeric (m) and dimeric (d) forms of replicative DNA intermediates, in both
tail-to-tail (T-T) and head-to-head (H-H) configurations, are depicted, the BglII restriction endonuclease sites are denoted by light blue arrowheads, and the
DNA fragments of the predicted sizes from each of the three plasmids are indicated. Southern blot analyses using a 32P-labeled DNA probe specific for hrGFP or
hGH(A)n would detect the characteristic AAV replicative DNA intermediates generated from the three indicated plasmids. Following cleavage with BglII and
probing with hrGFP, pLC1-hrGFP would generate only one band of 1.968 kb, pLC-2 would generate two bands of 2.155 kb and 4.310 kb, and pAAV-hrGFP
would generate two bands of 2.11 kb and 4.22 kb. Following cleavage with BglII and probing with hGH(A)n, pLC1-hrGFP would generate two bands of 0.717 kb
and 1.434 kb, pLC-2 would generate only one band of 0.53 kb, and pAAV-hrGFP would generate two bands of 0.672 kb and 1.344 kb.
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One-D-sequence-substituted ssAAV2 vectors efficiently
transduce human cells in vitro and murine hepatocytes in vivo.
To evaluate the transduction efficiency of one-D-sequence-sub-
stituted ssAAV2 vectors, a panel of human cell lines was infected
with each vector at 2,000 vgs/cell under identical conditions. The
WT vAAV2-hrGFP vector was used as an appropriate control. As
shown in Fig. 4A, in the commonly used HEK293 and HeLa cells,
the mutant vectors, vLC1-hrGFP and vLC2-hrGFP, yielded 8-
fold more green fluorescence, than the WT vector. In Huh7 and
U2OS cells, two cell lines less permissive for AAV2 vectors, we also
observed an 6-fold increase in the transduction efficiency. The
variation in transduction efficiencies was not affected when cells
were pretreated with MG132, a proteasome inhibitor, or Try23, a
specific inhibitor of cellular epidermal growth factor receptor
(EGFR) protein kinase (Fig. 4B), both of which are known to
significantly increase the transduction efficiency of ssAAV2 vec-
tors (13, 20), which indicates that neither intracellular trafficking
nor proteasome degradation is involved. Not surprisingly, coin-
fection with adenovirus type 2 (Ad2) led to similar levels of in-
crease in transgene expression mediated by the WT and the two
mutant vectors in HEK293 cells (Fig. 4B), presumably because
Ad2 coinfection is known to significantly increase the transduc-
tion efficiency of AAV vectors by augmenting the viral second-
strand DNA synthesis, leading to optimal transgene expression (4,
5). To further confirm the role of adenoviral genes, HEK293 cells
were transfected with pHelper plasmid, followed by infection with
either mutant or parental viral vectors. Again, the difference be-
tween increased transduction efficiencies was not significant (Fig.
4C). On the other hand, two other plasmids, pACG2, which ex-
presses AAV2 Rep and Cap proteins, and pRep78, which expresses
only Rep 78 but no Cap proteins, had no effect. In order to obtain
more quantitative data, we also performed flow cytometric anal-
ysis using both HeLa and HEK293 cells. As can be seen in Fig. 4D
and E, both the GFP positivity and the mean fluorescence values
were increased in both vLC1-hrGFP- and vLC2-hrGFP-infected
cells compared with vAAV-hrGFP-infected cells. Quantitative
analyses of the flow cytometric data for GFP expression mediated
by these vectors in HeLa (Fig. 4F) and HEK293 (Fig. 4G) cells are
also shown.
The efficacies of one-D-sequence-substituted vLC2-hrGFP
FIG 2 Effect of one D-sequence replacement on viral genome encapsidation. (A) Quantitative DNA slot blot analyses for the efficiency of packaging of the rAAV
genomes from the recombinant plasmids. The titer of each rAAV vector was determined by comparison with double-stranded plasmid pAAV-hrGFP standards
loaded onto the membrane. (B) Southern blot analysis of the nature of the rAAV DNA genomes in vector stocks. Equivalent volumes of DNA samples were
denatured at 65°C for 30 min and electrophoresed on alkaline agarose gels. (C) Western blot analysis of denatured viral capsids from vector stocks. (D)
Quantitative DNA slot blot analyses for determination of polarity of the mutant rAAV vector genomes. Two identical membranes were hybridized separately with
one of the two complementary 32P-labled oligonucleotides derived from the hrGFP plasmid. The hrGFP() (upper panel) and the hrGFP() (lower panel)
probes hybridize with the minus strand and the plus strand of AAV DNA, respectively. The parental virus vAAV-hrGFP, which packages both strands, was
included as a control.
FIG 3 Southern blot analyses of replicative DNA intermediates containing sub-
stitutions in the D sequence. HEK293 cells were infected with equal amounts of
vLC1-, vLC2-, or vAAV-hrGFP virions, followed by transfection with plasmids
pACG2 and pHelper. Low-Mr DNA was isolated at 72 h posttransfection. DNA,
with or without BglII digestion, was then separated by neutral agarose gel electro-
phoresis, followed by hybridization with 32P-labled DNA probes specific either for
hrGFP (left panel) or for hGH(A)n (right panel).
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FIG 4 Transduction efficiency of one-D-sequence-substituted recombinant AAV vectors in vitro. (A) Comparison of transduction efficiencies of vLC1-, vLC2-, and
vAAV-hrGFP vectors in permissive cell lines (HEK293 and HeLa) and in less permissive cell lines (Huh7 and U2OS). Cells were infected with viral vectors at 2,000 vgs/cell
for 2 h. Transgene expression was determined by fluorescence microscopy at 72 h posttransduction. (B and C) Fold changes in transgene expression mediated by vLC1-,
vLC2-, and vAAV-hrGFP vectors in HEK293 cells. Cells were infected with viral vectors at 2,000 vgs/cell for 2 h, together with treatment with chemicals or coinfection
with adenovirus 2 (B) or transfection with the indicated plasmids (C). Transgene expression was determined by fluorescence microscopy at 72 h posttransduction. A
change of 2.5-fold (horizontal line) was considered greater than the variability of the assay. (D and E) Transduction efficiencies of vAAV-hrGFP, vLC1-hrGFP, and
vLC2-hrGFP vectors in HeLa (D) and HEK293 (E) cells. Cells were transduced with the vectors at 2,500 vgs/cell for 4 h under identical conditions, and transgene
expression was determined by flow cytometry at 72 h posttransduction. Both EGFP positivity and mean fluorescence values are shown in red. (F and G) Representative
flow cytometry data from each group (n  3 for each cell type) for HeLa (F) and HEK293 (G) cells.
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vector and the parental vAAV-hrGFP vectors were evaluated in a
mouse model in vivo. C57BL/6J mice were injected via the tail vein
with 1 	 1010 vgs of each viral vector. Up to 6 weeks postinjection,
vAAV-hrGFP transduction was low and restricted to a small frac-
tion of the hepatocytes, which is consistent with previous obser-
vations (15). The transduction efficiency of vLC2 vectors was sig-
nificantly higher even at 2 weeks (data not shown). To more
accurately determine the transgene expression levels, persistence
of expression, and anatomical localization of the delivered trans-
genes in individual animals over time, we generated recombinant
WT and D-sequence-substituted ssAAV2-firefly luciferase (Fluc)
vectors under the control of the chicken -actin promoter
(CBAp). The CBAp was used to avoid promoter shutoff, a known
issue to which the CMV promoter in AAV vector is prone in the
liver (34). Approximately 1 	 1010 vgs of vAAV-Fluc, vLC1-Fluc,
and vLC2-Fluc vectors (Fig. 5A) were injected via the tail vein in
C57BL/6J mice. Whole-body bioluminescence images (Fig. 5B),
acquired as detailed in Materials and Methods at either 1 or 8
weeks postinjection, also corroborated that whereas little trans-
gene expression occurred in mice injected with the WT vAAV-
Fluc vectors, expression from both mutant vectors, vLC1-Fluc
and vLC2-Fluc, was up to 6-fold higher (Fig. 5C). These data dem-
onstrate that the one-D-sequence-substituted ssAAV vectors me-
diate accelerated and robust transgene expression compared to
the conventional ssAAV vectors in murine hepatocytes in vivo.
DISCUSSION
The unique structure of the 145-nt-long AAV ITR has been in-
triguing, since only the terminal 125 nt fold over to form a T-
shaped hairpin, which at a first glance would appear to suffice for
the priming of replication of the ssAAV genome, but the ITR also
contains a stretch of 20 nt, designated the D sequence, which is
single stranded. Nearly 2 decades ago, we and others embarked
upon investigations to delineate the precise role of the D sequence
in the life cycle of WT AAV2 and documented that it plays a
pivotal role in AAV genome rescue, replication, packaging, and
integration (18–20, 32, 33). However, the fundamental question
related to the underlying mechanisms of the involvement of the D
sequence in transgene expression from rAAV vectors remained
unanswered. The subsequent realization that the two D sequences
in a rAAV genome were not identical, but in fact were comple-
mentary to each other, and that the ssD[] sequence was always
present at the 3= end and the ssD[] sequence was invariably
present at the 5= end of the viral genome prompted us to explore
the possibility of the existence of putative host cell proteins which
might interact with these sequences.
Indeed, using both ssD[]- and ssD[]-sequence probes in
electrophoretic mobility shift assays (EMSAs), we were able to
identify two distinct cellular proteins that formed specific com-
plexes with the ssD[] and the ssD[] sequences, respectively
(6). In an extensive set of experiments, we identified the ssD[]-
FIG 5 Transduction efficiency of one-D-sequence-substituted recombinant AAV vectors in vivo. (A) Schematic structures of recombinant AAV vector plasmids.
CBAp, chicken -actin promoter. (B) Bioluminescence imaging of mice injected with AAV2-Fluc vectors. C57BL/6J mice were injected with 1 	 1010 vgs of either
vAAV-Fluc (left panels), vLC1-Fluc (middle panels), or vLC2-Fluc (right panels). Images were acquired with a Xenogen IVIS imaging system at 1 week or 8 weeks
postinjection. Images of two representative animals from each group are shown. (C) The luminescence signal intensity was quantified as photons/second/cm2/
steridian using the Living Image software.
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sequence-binding protein (13) and characterized the crucial role
that it plays in modulating the viral second-strand DNA synthesis
(6, 7, 13–16, 35, 36). The identity of the ssD[]-sequence-binding
protein was also revealed recently (17) as a negative regulator of
transcription. These observations that proteins binding with the
two D sequences at each end of a viral genome are both involved in
the inhibition of transgene expression led to the systematic studies
described here. The experimental data shown in Fig. 4 and 5 sug-
gested that the replacement of one D sequence partially relieves
this negative regulation. In this context, it is important to note that
in our previously published studies (32, 33), in which we deleted
18 nt of the D sequence, we did not observe any increase in the
transduction efficiency of these vectors. In the current studies, not
only was the entire 20-nt D sequence deleted but it was replaced
with a non-AAV substitute (S) sequence. Since we consistently
observed improved transduction of these vectors in a number of
human cell lines in vitro, as well as in murine hepatocytes in vivo,
it was important to gain a better understanding of the observed
differences from our previously published studies. To this end, we
performed computational analyses of both the D sequence and the
S sequence using the databases available at chip-mapper.org
and http://www.cbrc.jp/research/db/TFSEARCH.html (37, 38),
which allow the identification of putative transcription factor-
binding sites in DNA genomes. These results revealed that the
deletion of 18 nt from the D sequence leads to the loss of putative
binding sites for 2 transcription factors (Sry-delta and Nkx2-1),
whereas insertion of the S sequence provides putative binding sites
for 2 transcription factors (Foxd3 and NF-muE1). Thus, the net
result is not only the loss of a negative regulator of transcription
(NRF) but also the gain of 2 positive regulators of transcription in
the D-sequence-substituted AAV vectors, which provides a plau-
sible explanation as to why the vectors that have 18nts deleted
from the D sequence do not show superior transduction, whereas
the S-sequence-substituted AAV vectors do. A more stringent
search, with a threshold score of 85, which provides a higher confi-
dence value for binding of putative transcription factors, revealed that
the D sequence contains the binding site for GATA-1, whereas the S
sequence contains binding sites for both GATA-1 and GATA-2 tran-
scription factors. Thus, the loss of GATA-1 binding from the D-se-
quence-deleted AAV vectors and the acquisition of GATA-1 and
GATA-2 binding in the S-sequence-substituted AAV vectors pro-
vide yet another plausible explanation for the observed difference
between our previously published studies (32, 33) and those de-
scribed here. It should be emphasized, however, that these expla-
nations are based on theoretical computation only, and thus ad-
ditional studies involving the use of electrophoretic mobility shift
assays (EMSAs) are warranted to further corroborate this conten-
tion.
Together, these observations raise an interesting existential
question. Why, unlike all other DNA genome-containing organ-
isms, does the WT AAV remain single-stranded? One plausible
answer is that in order to maintain its cryptic life cycle, AAV must
exert enormous efforts to ensure that little viral gene expression
occurs in the absence of a helper virus. We would like to suggest
that the WT AAV does so by employing a “dual safety net.” In the
first instance, the D[] sequence is utilized to provide the binding
site for a host cell protein, FKBP52, phosphorylated forms of
which strongly inhibit the viral second-strand DNA synthesis
(13), since the extent of viral second-strand DNA synthesis corre-
lates directly with the efficiency of viral gene expression. In the
second instance, and in the event that some cell types might allow
even a low-level conversion to transcriptionally active double-
stranded viral genomes, AAV employs the D[] sequence to neg-
atively regulate viral gene expression. How such a negative effect is
rescued by the presence of adenoviral gene products, as shown in
Fig. 4B and C, warrants further studies.
Given these built-in features, it would appear that the WT sin-
gle-stranded AAV is less than ideal to be used as a recombinant
vector for gene therapy to achieve high-level transgene expression.
Our initial attempts to develop rAAV vectors devoid of both of the
D sequences in one rAAV genome did not succeed, as these ge-
nomes failed to undergo encapsidation into rAAV capsids (18–
20). In the present studies, however, in which we deleted only
one of the two D sequences in two respective plasmids, abun-
dant rescue followed by replication and encapsidation of the
viral genomes ensued, albeit at 50% efficiency because only
single-polarity S-sequence-substituted progeny AAV genomes
are generated and packaged, in contrast to their unmodified
counterparts, which are known to generate and encapsidate
progeny strands of both polarities that are packaged in mature
particles with equal frequency.
In sum, the studies described here, in addition to providing
insights into the basic biology of AAV, also provide a means to
achieve augmented transgene expression from a conventional
ssAAV vector by simply deleting the D sequence in the right ITR.
Given the fact that this strategy has also been successful using
AAV serotype 3 vectors (unpublished data), we believe that it
should be applicable to any conventional ssAAV serotype vec-
tor. Furthermore, combining these strategies with our recently
described next generation of AAV vectors containing muta-
tions in surface-exposed tyrosine, serine, and threonine resi-
dues (39–41) should further augment the transduction effi-
ciency of all conventional ssAAV vectors for their potential use
in human gene therapy.
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